These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32209728)

  • 1. Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing
    Hu L; Zhang S; Quan S; Lv J; Qian W; Huang Y; Lu W; Sun Y
    Aging (Albany NY); 2020 Mar; 12(6):4918-4930. PubMed ID: 32209728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
    Bergh C; Howles CM; Borg K; Hamberger L; Josefsson B; Nilsson L; Wikland M
    Hum Reprod; 1997 Oct; 12(10):2133-9. PubMed ID: 9402268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
    Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
    J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jan; 14():1. PubMed ID: 26733057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
    Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
    Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study.
    Revelli A; Chiado' A; Guidetti D; Bongioanni F; Rovei V; Gennarelli G
    J Assist Reprod Genet; 2012 Sep; 29(9):869-75. PubMed ID: 22644636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.
    Yong PY; Brett S; Baird DT; Thong KJ
    Fertil Steril; 2003 Feb; 79(2):308-15. PubMed ID: 12568839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin-releasing hormone antagonist protocol.
    Šprem Goldštajn M; Dumančić S; Mikuš M
    J Obstet Gynaecol Res; 2021 Mar; 47(3):992-1001. PubMed ID: 33372397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
    Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
    Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
    Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
    Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.